Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 69.4% from a year ago
Cash & equivalents stood at $30.07M at the end of Q1 FY2026, down 69.4% from a year earlier and up 43.3% from the prior quarter. Over 3 fiscal years it compounded at -15.1% a year.
Context
- Cash & equivalents amounted to 22.6% of total assets at the end of Q1 FY2026, down 33.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -69.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 20.99M USD
- Year-over-year change
- -42.4%
- 4-year CAGR
- -24.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.99M | -42.4% |
| FY2024 | 2024-12-31 | 36.44M | -35.2% |
| FY2023 | 2023-12-31 | 56.22M | +63.8% |
| FY2022 | 2022-12-31 | 34.32M | -47.8% |
| FY2021 | 2021-12-31 | 65.8M | — |
Cash & Equivalents vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -69.4% is the 10th highest of 11, against a peer median of +38.8%.
- Cash & equivalents amounts to 22.6% of total assets for BDTX, versus a peer median of 35.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | $88.91M USD | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $80.89M USD | +50.4% | +1.8% | 59.9% | |
| Mar 2026 | $62.44M USD | +135.6% | +44.6% | 63.3% | |
| Mar 2026 | $61.37M USD | +285.1% | +76.7% | 30.9% | |
| Mar 2026 | $47.32M USD | +31.9% | +21.0% | 0.0% | |
| Mar 2026 | $40.18M USD | +77.2% | +15.6% | 55.9% | |
| Mar 2026 | $34.93M USD | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $30.07M USD | -69.4% | -15.1% | 22.6% | |
| Mar 2026 | $24.99M USD | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $12.06M USD | -59.0% | -40.4% | 8.1% | |
| Peer median (excluding BDTX) | — | +38.8% | +11.0% | 35.4% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65.8M | 34.32M | 56.22M | 36.44M | 20.99M |
| Short-term Investments | 143.99M | 88.49M | 75.18M | 62.14M | 107.66M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.9M | 2.63M | 2.6M | 3.79M |
| Total Current Assets | 215.7M | 127.71M | 134.03M | 101.18M | 132.44M |
| Property, Plant & Equipment (Net) | 30.74M | 27.38M | 23.71M | 20.4M | 9.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 829K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.24M | 1.17M | 823K | 1.07M | 73K |
| Total Non-current Assets | 31.98M | 28.55M | 24.53M | 21.46M | 10.57M |
| Total Assets | 247.68M | 156.26M | 158.57M | 122.64M | 143.01M |
| Account Payables | 4.11M | 1.88M | 2.32M | 4.01M | 579K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 23.64M | 15.26M | 19.65M | 20.57M | 15.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 28.14M | 25.3M | 22.19M | 18.78M | 15.07M |
| Total Liabilities | 51.78M | 40.56M | 41.83M | 39.36M | 30.8M |
| Common Stock | 5K | 5K | 7K | 7K | 8K |
| Retained Earnings | (243.82M) | (334.99M) | (417.43M) | (487.11M) | (464.74M) |
| Accumulated OCI | (414K) | (1.82M) | (27K) | 24K | 101K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 195.9M | 115.7M | 116.74M | 83.29M | 112.21M |
| Total Debt | 28.46M | 28.14M | 25.3M | 22.19M | 18.78M |
| Net Debt | (37.34M) | (6.18M) | (30.92M) | (14.25M) | (2.21M) |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.